Labiana Health (XMAD:LAB) Debt-to-EBITDA : -6.72 (As of Dec. 2022)

View and export this data going back to 2022. Start your Free Trial

What is Labiana Health Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Labiana Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was €20.01 Mil. Labiana Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was €18.19 Mil. Labiana Health's annualized EBITDA for the quarter that ended in Dec. 2022 was €-5.69 Mil. Labiana Health's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2022 was -6.72.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Labiana Health's Debt-to-EBITDA or its related term are showing as below:

XMAD:LAB's Debt-to-EBITDA is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 1.715
* Ranked among companies with meaningful Debt-to-EBITDA only.

Labiana Health Debt-to-EBITDA Historical Data

The historical data trend for Labiana Health's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labiana Health Debt-to-EBITDA Chart

Labiana Health Annual Data

Trend

Dec20

Dec21

Dec22

Debt-to-EBITDA

7.20

8.94

-42.73

Labiana Health Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22
Debt-to-EBITDA	N/A	N/A	11.17	-6.72

Competitive Comparison of Labiana Health's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Labiana Health's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Labiana Health's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Labiana Health's Debt-to-EBITDA falls into.

Labiana Health Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Labiana Health's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(20.008	+	18.189)	/	-0.894
	=	-42.73

Labiana Health's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(20.008	+	18.189)	/	-5.686
	=	-6.72

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2022) EBITDA data.

Labiana Health (XMAD:LAB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Labiana Health Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Labiana Health's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Labiana Health (XMAD:LAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Labiana Health SA (XMAD:LAB) » Definitions » Debt-to-EBITDA

Traded in Other Exchanges

N/A

Address

Avenida Europa, 34 1st D, Pozuelo de Alarcon, Madrid, ESP, 28023

Website

https://www.labiana.com

Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include GMP manufacturer for EU animal and human health industries, manufacturer specialized in sterile and lyophilized dosage forms, source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol.